Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Philip De Jager, MD · PRINCIPAL_INVESTIGATOR · Columbia University
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Correlation between the chromosome 1 variant (rs2997325) and TSPO bindingUp to 1 year
The measure will be in vivo validation of GWAS and assessment of clinical relevance by performing TSPO PET imaging using 11C-ER176 to measure microglial activation. PET images will be analyzed using 1) the two-tissue kinetic model to calculate total distribution volume, corrected for free fraction of radioligand in plasma (VT/fP). Analysis will be a meta-analysis of the association of rs2997325 with 11C-ER176 binding (total distribution volume, VT).
- Number of variants discovered in genome-wide association study (GWAS) that influence TSPO bindingUp to 1 year
11C-ER176 data will be used to perform a discovery GWAS for additional variants that influence TSPO binding and to define the genetic architecture of the PAM trait. Using PLINK and all imputed high quality genotypes (imputation r2 \>0.8), adjusted for sex, age, and technical variables, the investigators will perform a GWAS for TSPO binding.